Small firm benefits from major COVID-19 contract

20 May 2020
drugpricebigv2

The US government has awarded $354 million to a start-up, Phlow Corporation, to boost local production of drugs at risk of shortage, including medicines to treat COVID-19.

A newly-founded company with an explicitly nationalistic aim, Phlow has committed to working with physician-led Civica Rx, a generics company  founded in 2018 to alleviate pricing pressure on hospitals.

Provided by the Biomedical Advanced Research and Development Authority (BARDA), the funds are for a four-year contract, and could be increased by $458 million, based on unspecified “long-term sustainability” goals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics